Abstract:e19008 Background: Stage IV non-small cell lung cancer (NSCLC) carries a poor prognosis with a median survivals of 8-10 months. The standard treatment has traditionally been systemic chemotherapy and palliative radiotherapy for symptom relief. Some data has suggested that patients with oligometastatic NSCLC may benefit from aggressive thoracic radiotherapy. The aim of this study was to evaluate the efficacy and toxicity of definitive thoracic concurrent chemoradiation followed by consolidation chemotherapy in oligometastatic NSCLC. Methods: Patients with oligometastatic NSCLC, aged ≤ 75 years, and WHO performance status of 0-1 were enrolled. Oligometastatic NSCLC was defined as 5 or fewer distant metastatic lesions at diagnosis. Patients were treated with definitive thoracic radiotherapy (biological equivalent dose ≥ 60Gy) concurrent with platinum-based, two-drug chemotherapy. After concurrent chemoradiation, patients received 2-4 cycles of consolidation chemotherapy. The primary endpoint was progression-free survival (PFS). Secondary end points were objective remission rate (ORR), overall survival (OS) and toxicity. Results: Between Jane 2008 and Jane 2013, 64 patients were enrolled. Median age was 62 years (range: 41-70 years). Median prescribed radiation dose to primary tumor was 72Gy. The median number of chemotherapy cycles was 4 (range 2-6). The confirmed ORR was 70.3% (10.9% CR and 59.4% PR). At a median follow-up of 28 months, the median PFS and OS were 14 months and 26 months, respectively. The 1-, 2-, and 3-year PFS were 56.3%, 25.6%, 7.4%, respectively. The 1-, 2-, 3-, 4-, and 5-year OS were 71.9%, 52.5%, 31.4%, 25.1% and 14.8%, respectively. Toxicities were generally mild, including grade 2/3 radiation pneumonitis (10.9%), grade 2/3 radiation esophagitis (17.2%), grade 3/4 neutropenia (39.1%), grade 3/4 thrombocytopenia (15.6%), and grade 3/4 anemia (10.9%). Conclusions: Thoracic concurrent chemoradiation followed by consolidation chemotherapy showed a promising efficacy and an acceptable tolerability profile for patients with oligometastatic NSCLC. Further larger and randomized controlled trials are warranted.

A Phase II Prospective Study of Definitive Thoracic Concurrent Chemoradiation Followed by Consolidation Chemotherapy for Oligometastatic Non-Small Cell Lung Cancer.